Homepage Top Section2

The company has reported positive headline results from the pivotal DREAMM-2 open-label and randomised study of two doses of belantamab mafodotin. Belantamab mafodotin is an immuno-conjugate, which included

Cabotegravir is an investigational integrase inhibitor (INI) developed by ViiV Healthcare, while Edurant (rilpivirine) has been developed by Janssen as a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the

The new facility is believed to support the company’s continuing investment in gene therapy research and development similar to its research and development sites in Chapel Hill and

As per the terms of the deal, Bayer will receive $5.3bn (£4.37bn) in cash and will be issued $2.3bn (£1.9bn) worth shares in the US-based Elanco Animal Health.

The investment secured by Sanfer is expected to help the company implement its continued expansion plans in Mexico and in other parts of Latin America. Additional terms of

The company has also received accelerated approval for Rozlytrek to treat adult and paediatric patients 12 years of age and older with solid tumours, which have a neurotrophic

The approval has been granted for the use of ibrutinib in combination with obinutuzumab in adult patients with previously untreated chronic lymphocytic leukaemia (CLL), as well as the

As per terms of the deal, the former Cavion shareholders have secured an upfront payment of $52.5m (£43.5m). They are also eligible to receive additional payments of around

The company has announced positive OS results from the phase III randomised, double-blinded and multi-centre trial of Tagrisso in previously-untreated patients with locally-advanced or metastatic non-small cell lung